Form 4 for CTMX CytomX Therapeutics, Inc.
Accepted 2023-02-06 00:00:00 ET · period of report 2023-02-02 · accession 0001567619-23-001927 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-02-06 | 2023-02-02 | CTMX | Ogden Christopher | SVP, Fin, Accounting | A - Grant | $0.00 | +25.0K | 38.3K | +188% | $0 |
| DM | 2023-02-06 | 2023-02-02 | CTMX | Ogden Christopher | SVP, Fin, Accounting | A - Grant | $0.00 | +150.0K | 75.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-02 | A | A | 25,000 | $0.00 | 38,288 | D | — | — | (F1) Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on Febrary 2 of each year, with the first 1/3rd vesting on February 2, 2024, subject to the Reporting Person continuing as a service provider through each such date. (F3) Includes 6,000 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on November 30, 2022. (F2) Includes 32,288 RSUs. |
| 2 | Derivative | Performance Stock Units (PSUs) | 2023-02-02 | A | A | 75,000 | $0.00 | 75,000 | D | — · — to — | 75,000 Common Stock | (F5) Each Performance-Based Restricted Stock Unit ("PSU") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/2 of the PSUs vest upon the achievement of each of two clinical milestones, subject to the Reporting Person continuing as a service provider through each such date. |
| 3 | Derivative | Stock Option (Right to Buy) | 2023-02-02 | A | A | 75,000 | $0.00 | 75,000 | D | $2.59 · — to 2033-02-01 | 75,000 Common Stock | (F4) 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 2, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. |